ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Metal-Organic Framework-Preserved Thermostable Microneedle Patch for Minimally Invasive Detection and Monitoring of Kidney Dysfunction.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Early and decentralized biomarker detection and monitoring is essential for timely diagnosis and intervention, particularly in kidney disorders that often progress asymptomatically until irreversible damage has occurred. Here, we present a thermally resilient metal-organic framework encapsulated microneedle (MOF@MN) sensing platform that integrates minimally invasive dermal interstitial fluid (ISF) sampling and on-needle detection with MOF-based biostabilization of the sensing interface. A thin zeolitic imidazolate framework-8 (ZIF-8) shell is grown in situ on antibody-functionalized microneedles, preserving the bioactivity of immobilized antibodies after 4 weeks of thermal cycling up to 50°C and maintaining full analytical performance after prolonged unrefrigerated shipment. This interfacial encapsulation strategy enables quantitative detection of neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker of kidney injury, directly from dermal ISF over a broad clinically relevant range. In a mouse model and human subjects, MOF@MN-derived NGAL measurements closely mirror blood NGAL concentrations, precede changes in conventional renal function markers, and correlate well with histopathological injury severity, highlighting their potential for subclinical monitoring. Collectively, this study establishes conformal MOF encapsulation as a simple and highly effective strategy for engineering environmentally resilient sensing interfaces and provides a scalable route to cold-chain-independent, minimally invasive biosensing for decentralized and at-home health monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.